France's Biosimilar Law May Set Trend Inside The EU

Law360, New York (February 18, 2014, 6:26 PM EST) -- Beginning on Jan. 1, 2014, French pharmacists are now legally permitted to substitute a biosimilar for the prescribed (reference) biological medicine, as long as the prescribing physician has not marked the prescription as “nonsubstitutable.” While the details will be defined via the enactment of implementing decrees, under the 2014 Social Security Financing Law ("SSFL"), substitution will be allowed only when initiating a course of treatment, and if the biosimilar belongs to the same group as the prescribed product, known as a “similar biologic group.”

Importantly, the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.